Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189074 | 0.96 | KDM4E (0.54) | KDM4EALDH1A1PIK3CGHTTKMT2A | |
| SCHEMBL13416401 | 0.91 | PIK3CG (0.51) | KDM4EALDH1A1PIK3CGHTTKMT2A | |
| SCHEMBL13416234 | 0.88 | PIK3CG (0.52) | KDM4EALDH1A1PIK3CGHTTKMT2A | |
| SCHEMBL13416106 | 0.87 | PIK3CG (0.55) | KDM4EALDH1A1PIK3CGHTTKMT2A | |
| SCHEMBL13416538 | 0.87 | PIK3CG (0.51) | KDM4EALDH1A1PIK3CGHTTKMT2A | |
| SCHEMBL13416520 | 0.87 | PIK3CG (0.51) | KDM4EPIK3CGKMT2APIK3CDPIK3CA | |
| SCHEMBL13416286 | 0.87 | SMN1; SMN2 (0.56) | KDM4EALDH1A1PIK3CGHTTKMT2A | |
| SCHEMBL13416508 | 0.86 | PIK3CG (0.50) | KDM4EALDH1A1PIK3CGHTTKMT2A | |
| SCHEMBL189874 | 0.86 | PIK3CG (0.54) | KDM4EALDH1A1PIK3CGHTTKMT2A | |
| SCHEMBL13416314 | 0.86 | PIK3CG (0.49) | KDM4EALDH1A1PIK3CGHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | KDM4E 761/4885ALDH1A1 4075/4885PIK3CG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.